2016 Support

Takeda UK support provided to Patient Organisations during 2016. Takeda Products Ireland Ltd have not supported any Patient Organisations during 2016.


Patient Organisation Amount   Involvement
Bloodwise £10,000 Funding towards the development of Blood Cancer Connect an online resource for blood cancer patients.
Crohn's and Colitis UK £1,666.67 Speaker fees for internal events
Crohn's and Colitis UK £5,000 Funding to support printing of My Crohn's & Colitis Care [patient information leaflet]
Crohn's and Colitis UK £13,000 Funding towards the further development, printing and distribution of 8,000 patient information packs  
Crohn's and Colitis UK £500 Charitable donation following 'Walk It' sponsored charity walk on 4th June 2016
Diabetes UK £200 Charitable donation    
Diabetes UK £3,000 Bronze sponsorship of DUK Conference     
Diabetes UK £540 Purchase of exhibition space at a regional diabetes meeting
Endometriosis UK £14,200 Funding towards producing a new version of 'Living with Endometriosis' patient information booklet
Leukaemia CARE £15,000  Core funding to support ongoing activities such as a 24 hour freephone CARE line, patient information booklets, support groups and patient, carer and nurse conferences
Lymphoma Association £2,800 Exhibition stand space at 5 meetings
Lymphoma Association £2,000 Funding towards the cost of Lymphoma UK's fundraising materials
Lymphoma Association £725 Charitable donation
Myeloma UK £50,000 Core funding to support  ongoing activities related to myeloma patients and their families 
Myeloma UK £16,565.56 Charitable donation
Myeloma UK £136.14 Speaker expenses for internal event
React £5,200 Funding towards the production of the React biannual patient newsletter
Sarcoma UK (British Sarcoma Group)  £2,833 Purchase of exhibition space 
The Urology Foundation £2,000 Charitable donation



Takeda UK clinical research support provided to Patient Organisations during 2016.

Patient Organisation Amount Involvement
Myeloma UK £5,924,160 Benefit in kind value of investigational product provided free of charge for the conduct of an investigator initiated clinical trial in the Myeloma UK Clinical Trial Network (Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma - MUKEight; NCT02461888) 
Study Sponsor: Leeds University 
Collaborators: Myeloma UK; Millennium Pharmaceuticals (a wholly subsidiary of Takeda Pharmaceutical Company Ltd)






Date of Preparation: July 2019